Efficacy and safety of ferulic acid and Angelica archangelica extrac in patients with mild cognitive impairment (MCI): Double blind placebo-controlled study - FAMCIS

Hokuriku National Hospital0 个研究点目标入组 20 人开始时间: 2014年7月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.MCI outpatients older than 60 years old at informed consent.
•2.Patients with MCI who fulfilled the MCI criteria (Reisberg(1991); MayoClinic,Petersen(1995)).
•3.MMSE score 20-26 points and CDR score 0.5 or 1.
•4.Patient could be distinguished from other dementia disorders.
•5.Patient can administrate the tablets and patient and patient's family can manage taking medicine.
•6.Written informed consent of patient and patient's family.

•1.Patients taken supplements which contain polyphenols within 1 month.
•2.Patients with severe heart disease, liver disease, kidney disease.
•3.Patients who has malignancy.
•4.Patients who has previous history of alcohol and/or drug abuse.
•5.Patients who has hypersensitivity to polyphenols.
•6.Patients who has drug and/or food allergy.
•7.Patients participating in other clinical trials.
•8.Patients newly administrated other dementia therapeutics within 30 days including Galantamine Hydromide (Reminyl, Takeda pharmaceutical company limited. Janssen pharmaceutica), Memantine Hydrochoride (Memary, DaiichiSankyo company limited), Rivastigmine (Exelon patch, Novartis/ Rivastach patch, Ono pharmaceutical company limited), Donepezil Hydrochloride (Aricept, Aricept D, Eisai). During this trial, addition and change of other dementia therapeutic drugs are not permitted in principle.
•9.The patients judged to inadequacy by the attending physician or principal investigator.

发起方

Hokuriku National Hospital